Form 7 Monthly Progress Report October 2023
Form 7 Monthly Progress Report October 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 November 3, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report September 2023
Form 7 Monthly Progress Report September 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 October 1, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis This article recently appeared in the French-Canadian news publication “Le Soleil”. The origjnal article can be found here: https://www.lesoleil.com/affaires/2023/08/30/une-technologie-dici-pour-mieux-diagnostiquer-le-cancer-du-poumon-WMYOCY325FC65HU4ISBUQWJT5U/ The following is an AI translation of the text of the article to English: “Local Technology for Improved […]
BioMark appointS Kevin J. Cosgriff TO ITS STRATEGIC Advisory Team
Vancouver, British Columbia – (August 30th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that Vice Admiral Kevin Cosgriff will be joining BioMark’s Advisory team to support its innovation and […]
Form 7 Monthly Progress Report August 2023
Form 7 Monthly Progress Report August 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 September 1, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
JAPAN PATENT OFFICE (JPO) ISSUEDD BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED LIQUID BIOPSY ASSAY
JAPAN PATENT OFFICE (JPO) ISSUED BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED LIQUID BIOPSY ASSAY New family of patent granted by Japanese Patent Office enhances BioMark’s global intellectual property position in lung cancer detection using urine as a convenient biological sample medium. Vancouver, British Columbia – (August 8th, 2023) – BioMark Diagnostics […]
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update Vancouver, British Columbia – (July 25th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard-to-detect and treat cancers issued a statement today commenting on the recent market activity. […]
Form 7 Monthly Progress Report July 2023
Form 7 Monthly Progress Report July 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 August 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report June 2023
Form 7 Monthly Progress Report May 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 July 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual Meeting
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual Meeting BioMark’s blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting. Vancouver, British Columbia – (June 5th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with […]
